Robin Patel, MD

Financial relationships

  • Attribution: 
    Self
    Ineligible company: 
    ContraFect, TenNor Therapeutics Limited, Hylomorph and Shionogi
    Topic: 
    Research
  • Attribution: 
    Self
    Ineligible company: 
    Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, and Qvella
    Topic: 
    Consultant - Monies go to my employer
  • Attribution: 
    Self
    Ineligible company: 
    Netflix
  • Attribution: 
    Self
    Ineligible company: 
    Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued
  • Attribution: 
    Self
    Ineligible company: 
    Dr. Patel receives an editor’s stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course
Return to 2022 Infectious Disease Board Review Course